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Association analysis of PRNP gene region with
chronic wasting disease in Rocky Mountain elk
Stephen N White1,2,3*, Terry R Spraker4, James O Reynolds1, Katherine I O’Rourke1,2
Abstract
Background: Chronic wasting disease (CWD) is a transmissible spongiform encephalopathy (TSE) of cervids
including white-tailed (Odocoileus virginianus) and mule deer (Odocoileus hemionus), Rocky Mountain elk (Cervus
elaphus nelsoni), and moose (Alces alces). A leucine variant at position 132 (132L) in prion protein of Rocky
Mountain elk confers a long incubation time with CWD, but not complete resistance. However, variants in
regulatory regions outside the open reading frame of PRNP have been associated with varying degrees of
susceptibility to prion disease in other species, and some variants have been observed in similar regions of Rocky
Mountain elk PRNP. Thus, additional genetic variants might provide increased protection, either alone or in
combination with 132L.
Findings: This study provided genomic sequence of all exons for PRNP of Rocky Mountain elk. Many functional
sites in and around the PRNP gene region were sequenced, and this report approximately doubled (to 75) the
number of known variants in this region. A haplotype-tagging approach was used to reduce the number of
genetic variants required to survey this variation in the PRNP gene region of 559 Rocky Mountain elk. Eight
haplotypes were observed with frequencies over 1.0%, and one haplotype was present at 71.2% frequency,
reflecting limited genetic diversity in the PRNP gene region.
Conclusions: The presence of 132L cut odds of CWD by more than half (Odds Ratio = 0.43; P = 0.0031), which
was similar to a previous report. However after accounting for 132L, no association with CWD was found for any
additional variants in the PRNP region (P > 0.05).
Background
Chronic wasting disease (CWD) is a transmissible spon-
giform encephalopathy (TSE) of cervids including white-
tailed and mule deer (Odocoileus virginianus and
O. hemionus, respectively), Rocky Mountain elk (Cervus
elaphus nelsoni), and moose (Alces alces) [1]. This
invariably fatal disease can be associated with progres-
sive physical wasting, often accompanied by behavioral
changes including listlessness, decreased interaction with
other animals, decreased responsiveness to environmen-
tal stimuli, and repetitive behaviors [1]. There is no cure
for CWD or any of the TSEs, and current management
practice to reduce the spread of CWD includes depopu-
lation or permanent quarantine of infected farmed herds
as well as removal of free-ranging animals showing
clinical signs of disease. Despite these efforts, prevalence
continues to climb and the range of CWD continues to
expand [2,3].
The TSEs are believed to be caused by a misfolded
prion protein (PrPd) that is protease resistant and infec-
tious [4]. The prion protein is highly conserved and the
normal cellular form of the protein (PrPc) is expressed
in neurons of all mammals studied to date [5]. The dis-
ease form PrPd is capable of recruiting the normal cellu-
lar form of the protein (PrPc) into the same misfolded
conformation [4]. While there is no cure for CWD,
genetic variants in and around the prion gene confer
varying degrees of resistance to TSEs in a range of spe-
cies. In sheep, an arginine substitution at position 171
(171R) confers strong resistance to classical scrapie, the
TSE of sheep and goats [6]. Scrapie eradication pro-
grams in the U.S. and Europe include a large compo-
nent of breeding animals toward resistant genotypes,
and classical scrapie prevalence is in decline [7,8].
* Correspondence: swhite@vetmed.wsu.edu
1Animal Disease Research Unit, Agricultural Research Service, U.S.
Department of Agriculture, Pullman, WA 99164, USA
Full list of author information is available at the end of the article
White et al. BMC Research Notes 2010, 3:314
http://www.biomedcentral.com/1756-0500/3/314
© 2010 White et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Genetic solutions may be possible for Rocky Mountain
elk, and a leucine variant at position 132 (132L) in prion
protein confers a long incubation time with CWD, but
not complete resistance [9-11]. However, additional
genetic variants might provide increased protection,
either alone or in combination with 132L. Genetic var-
iants in regulatory regions outside the open reading
frame of the prion gene have been associated with sus-
ceptibility to or incubation time with prion disease in
cattle [12], and some genetic variants have been
observed in similar regions of Rocky Mountain elk
[9,13,14].
The many variants in any gene region are arranged in
only a limited number of haplotypes, or linear arrange-
ments of genetic variants as they exist on chromosome
segments in a population. To find an important genetic
variant, one need only genotype a limited set of variants
that “tag” all the major haplotypes in a gene region to
capture all or most of the information contained in the
complete set of genetic variants in a region [15]. This
strategy is known as haplotype-tagging, and it often
reduces the number of variants that need to be geno-
typed by 50-75% or more, greatly reducing the time,
cost, and complexity of analysis required to test a region
for important genetic variants [16,17]. Importantly,
because any disease-related variant will occur on one or
more haplotypes in the population, haplotype tagging
allows the testing of haplotypes for association with dis-
ease whether or not the underlying causative variants
are in the dataset, or even known at all. This has given
rise to a two-stage strategy for assessing genetic associa-
tion: first, a relatively small number of individuals are
genotyped to determine common haplotypes in a popu-
lation, and then all individuals are genotyped with only
a set of haplotype-tagging markers identified in the first
round [16]. Therefore, this study used a two-stage hap-
lotype-tagging strategy to search for any variants in the
PRNP gene region - whether previously known, discov-
ered in this study, or as yet undiscovered - that may
provide increased protection from CWD in Rocky
Mountain elk.
Methods
A total of 559 captive and free-ranging Rocky Mountain
elk were sampled from herds following positive CWD
diagnosis in 6 states including Colorado, Montana, Min-
nesota, Nebraska, Oklahoma, and South Dakota. All ani-
mal procedures used were exempt by the Institutional
Animal Care and Use Committee of Washington State
University as no live animal use was involved; all sam-
ples were from depopulation programs approved by fed-
eral and state regulatory bodies to control the spread of
CWD. In total, 120 animals tested positive and 439
tested negative for CWD by immunohistochemical
methods as previously described [10]. Briefly, formalin
fixed tissues including brain, retropharyngeal lymph
node, and tonsil were processed for PrPd detection
using an automated monoclonal antibody immunohisto-
chemistry assay [10]. The standard for considering an
animal CWD positive was at least one tissue positive for
PrPd. Because the time between infection and appear-
ance of detectable PrPd is unknown [3], elk from herds
exposed to CWD but individually lacking detectable
PrPd were not defined as CWD negative; these animals
were defined as herd-matched controls.
Sequence and Association Analysis
Genetic variant discovery was performed on a group of
20 animals chosen for geographic diversity, including
animals from Colorado, Montana, Minnesota, and Okla-
homa. PCR was performed using primers as shown
(additional file 1: amplification primers and conditions)
and the following standard PCR conditions: an initial
denaturation at 95 degrees for 5 minutes, followed by
35 cycles of 95 degrees for 30 seconds, the annealing
temperature (see additional file 1) for 30 seconds, and
68 degrees for 90 seconds, and a final extension step at
68 degrees for 10 minutes. Sequencing employed BigDye
chemistry (Applied Biosystems, Foster City, CA) and
primers as shown (additional file 2: sequencing primers).
The regions sequenced included the promoter, 5’ UTR,
entire open reading frame, 3’ UTR, all exon splice sites,
and flanking regions located approximately 20 kb
upstream of the sequenced promoter region and
approximately 20 kb downstream of exon 3. Deeper
resequencing using a subset of these primers was per-
formed on a group of 93 animals (46 cases, 47 controls)
to identify additional variants including lower frequency
alleles that may be associated with CWD.
Haplotype tagging markers (Table 1) were chosen
using an r2 threshold of 0.8 in Tagger as implemented
in HAPLOVIEW [18] to represent every variant present
at greater than 5% minor allele frequency in either the
geographic diversity group of 20 or in the case-control
group. Genotyping assays were designed for these haplo-
type-tagging markers (Tables 2, 3), and genotyping was
performed on the full animal set as previously described
[19]. Briefly, fluorescent TaqMan genotyping assays
were performed according to manufacturer specifica-
tions, including standard cycling conditions, (Applied
Biosystems, Foster City, CA) using primer and probe
sets as shown in Table 2. Restriction fragment length
polymorphism (RFLP) assays were performed using
standard PCR conditions (see above) and restriction
enzymes listed in Table 3 according to manufacturer
specifications (New England Biolabs, Ipswich, MA; Fer-
mentas Inc., Glen Burnie, MD; Roche Diagnostics,
Indianapolis, IN), and visualized on 2% (mass/volume)
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agarose gels. One haplotype-tagging marker (g.152T >
C; [dbSNP:ss115456962]) was not suitable for either
fluorescent or RFLP genotyping assays, so allele-specific
PCR was performed to identify genotypes for this mar-
ker. The reaction to detect the C allele of this marker
used standard PCR conditions (above) with a 51 degree
annealing temperature, and employed the following
primers: CTAGGTGGAATCAGTCGYAC and GGACT
TTGCCCAGAGGGTAG. The reaction to detect the T
allele was similar except for a 61 degree annealing tem-
perature, and it employed primers CTAGGTGGAAT-
CAGTCTYAT and GGACTTTGCCCAGAGGGTAG.
As with RFLP assays, the results were visualized on 2%
(mass/volume) agarose gels. The threshold for successful
marker genotyping was genotypes on at least 95% of
animals. Haplotype frequencies were calculated using
PHASE v2 (Table 4) [20,21]. The threshold for success-
ful genotypic markers was genotype identification in at
least 95% of animals with at least 95% confidence in
PHASE v2.
Baseline association of the 132L variant was per-
formed using the logistic procedure of SAS 9.2 (SAS
Institute, Cary, NC). Association analysis of other
markers while accounting for 132L was performed on
markers with greater than 5% minor allele frequency
using the logistic procedure of SAS 9.2 with a model
including the presence/absence of 132L in addition to
presence/absence of the variant of interest. Additionally,
similar logistic models were used to test full genotypes
while accounting for 132L by performing exact condi-
tional tests (to account for low minor allele frequencies)
for genotypes of 132L and the variant of interest. Fish-
er’s exact was used to perform specific comparison of
CWD frequency among L132-bearing haplotypes.
Results and Discussion
While it is clearly possible to have strong genetic resis-
tance to TSEs, Rocky Mountain elk have only been shown
to have the 132L substitution which confers extended
incubation time with CWD but not complete resistance
[9,10]. Additional variants in regulatory sites outside the
open reading frame could provide increased protection,
and this study used a haplotype-tagging approach to iden-
tify such variants. Specifically, this study expanded the
available genomic DNA sequence and variants in the
PRNP gene region, assessed haplotype structure in this
Table 1 Haplotype-tagging markers genotyped in PRNP gene region.
Marker dbSNP accession Sequence variant Minor Allele Minor Allele Frequency (%) Impact on PRNP
1 ss115456950 g.371T > C1 C 15.1
2 ss115456954 g.986A > G1 G 15.3
3 ss119994796 g.598T > C2 T 23.4
4 ss119994799 g.655C > T2 T 1.3
5 ss119994806 g.918A > G2 G 14.8
6 ss119994811 g.1131C > G2 G 13.4
7 ss119994818 g.1456C > G2 G 8.0
8 ss119994819 g.1477C > T2 T 23.5
9 ss119994821 g.1591T > C2 C 13.9
10 ss119994830 g.17361G > A2 A 23.9
11 ss119994833 g.17918T > G2 T 24.3
12 ss119994840 g.18059C > T2 T 22.4 Silent4
13 ss119994835 g.18308G > A2 G 8.5 Silent4
14 ss119994836 g.18390A > T2 T 13.4 L132M4
15 ss115456958 g.3C > T3 C 13.3
16 ss115456962 g.152T > C3 T 21.9
17 ss115456969 g.1104C > T3 C 8.3
18 ss119994818, ss119994835 g.1456C > G2, g.18308G > A2 CG 8.5
19 ss119994818, ss119994819 g.1456C > G2, g.1477C > T2 CT 23.3
20 ss115456954, ss119994833, ss119994836 g.986A > G1, g.17918T > G2,
g.18390A > T2
GTT 11.6
21 ss119994796, ss119994806 g.598T > C2, g.918A > G2 CA 23.6
22 ss119994796, ss119994806 g.598T > C2, g.918A > G2 TG 14.3
1Nucleotide positions in reference to GenBank:FJ590753.
2Nucleotide positions in reference to GenBank:FJ590751.
3Nucleotide positions in reference to GenBank:FJ590752.
4Deduced amino acid substitution.
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gene region in Rocky Mountain elk, and tested common
haplotype variants for association with CWD.
The current data study greatly expanded both the
genomic sequence and known variants in the PRNP
gene region of Rocky Mountain elk. As depicted in Fig-
ure 1, sequence data were generated on the proximal
promoter region, all exons and splice sites, the 3’UTR,
and flanking regions of the PRNP gene of Rocky Moun-
tain elk. The total sequence was over 7 kb from a region
spanning approximately 63 kb, of which over 40% was
not previously reported to the best of our knowledge
(Table 5). Further, the markers provided here approxi-
mately doubled the number of publically available var-
iants in the PRNP gene region to 75 (Table 5). Most of
these additional variants were obtained from the 20 elk
chosen for geographic diversity. There was only one
additional variant (dbSNP:ss119994812) observed from
the deeper resequencing of additional case-control ani-
mals, and it had a low minor allele frequency (0.5%) in
the case-control group.
As anticipated, these 75 total variants were found to
be organized into a much smaller number of haplotypes.
Out of 559 elk, only 19 haplotypes were observed 3 or
more times in the sample set, and only 8 haplotypes
were observed at 1.0% or greater allele frequency in the
total sample, with only small variations once subdivided
by captive or free-ranging state of the animals (Table 4).
However, since the free-ranging animals were obtained
from a smaller number of locations from only one state
and since captive animals have had documented human-
assisted gene flow, it is difficult to make any inferences
about the genetic diversity of captive versus free-ranging
animals from these data. Haplotype tagging enabled
representation of all common underlying variants at r2
of 0.80 or greater using only 17 SNP markers, plus 5
derived genotypes composed of short multimarker hap-
lotypes (Table 1). This represents a 77.3% reduction in
variants that needed to be genotyped, which is compar-
able to other reports for haplotype tagging strategies in
mammals [16,17]. Further, the haplotype tagging proce-
dure required coverage of every variant in each of two
animal groups, even though the variants observed in
each group varied somewhat. This approach was a con-
servative way to ensure that all markers received cover-
age, but at the expense of possibly overestimating the
number of markers required. The small number of hap-
lotypes reflects relatively limited diversity in the PRNP
gene region among Rocky Mountain elk [13], which is
consistent with other reports of low genetic diversity
using microsatellites in Rocky Mountain elk [22]. How-
ever, the paucity of studies based on comparable marker
types precludes conclusions regarding selective sweeps
in the PRNP region as compared to the rest of the gen-
ome. Overall, this group of tagging markers provided
representation of the genetic diversity in the PRNP gene
region for measuring local linkage disequilibrium
between gene regions and for association testing with
CWD.
These markers were used to investigate whether addi-
tional markers could improve the resistance provided by
the previously described 132L variant (O’Rourke et al
1999). The 132L variant was underrepresented among
CWD cases (P = 0.0031), occurring in cases less than
half as often as the predominant genotype 132 MM
Table 2 Fluorescent Genotyping Assays.
Sequence
variant
Reagent
Role
Oligonucleotide
g.655C > T2 Primer GCCTGGACTCCACCTTAGG
Primer CGATGAGTAACCTGGATACGATCAA
Probe4 TTCTGTTGTCGTTTCCT
Probe5 TCTGTTGTCATTTCCT
g.1131C > G2 Primer GCTACAACAGACTGACTGGATAGAA
Primer GGAATGAAGATGATTCAGTAATGGAAATGG
Probe4 CCAGTTAGAAATCAGTATTA
Probe5 CCAGTTAGAAATGAGTATTA
g.18390A > T2 Primer GCAGCTGGAGCAGTGGTA
Primer CAAAATGTATAAGAGGCCTGCTCATG
Probe4 TTCCCAGCATGTAGCC
Probe5 CCCAGCAAGTAGCC
g.1456C > G2 Primer GGAGCCTCTTGCCCATAACAA
Primer AGAAAACAGGTGTTAGAGGGATCATATACA
Probe4 ATTTATGCTGGGTCAATG
Probe5 TTATGCTGCGTCAATG
g.17361G > A2 Primer TCTGTGCCAGGCTCTGC
Primer AGGGAATGAGTCTCTTTTGTTTGCT
Probe4 CCTGGCCCACTAAGA
Probe5 CTGGCCCGCTAAGA
g.1104C > T3 Primer CCATGTGGAGGCCAGAAATCC
Primer GATGCCAGAAGAGTTTACAGAGACA
Probe4 CTGGAGGTGGGAAAC
Probe5 CTGGAGGTAGGAAAC
g.986A > G1 Primer ATCCCCTACCTATGACTTTCAGACA
Primer TCCCCATAACCCGGAATCCT
Probe4 ATCATAGGCTACTACCTCATT
Probe5 TAGGCTACTGCCTCATT
g.371T > C1 Primer GGACTGTCTAGATGAGCCAAACAT
Primer AGAGTCCCAGTTGCAGCTTAG
Probe4 AGGATGACCGAAATAT
Probe5 AGGATGACCAAAATAT
g.18308G > A2 Primer CACATGGTGGTGGAGGCT
Primer GCTCCTGCCACATGCTTCA
Probe4 TCAGTGGAACAAACCCAGT
Probe5 AGTGGAACAAGCCCAGT
1Nucleotide positions are based on GenBank:FJ590753.
2Nucleotide positions are based on GenBank:FJ590751.
3Nucleotide positions are based on GenBank:FJ590752.
4Taqman probe labelled with VIC dye. 5Taqman probe labelled with FAM dye.
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Table 3 Restriction Fragment Length Polymorphism Assays
Sequence variant Reagent Role Reagent Annealing Temp
g.598T > C2 Primer CGAACATGCTTGTCATTCAGT 58
Primer ATTTATGGCCTGTCTGGAGGA
Enzyme Bcl I
g.17918T > G2 Primer GCAAAATCTTGCCTGTTTCC 58
Primer GGGGAGGAGAAGAGGATCAC
Enzyme Nsi I
g.18059C > T2 Primer GCAAAATCTTGCCTGTTTCC 58
Primer GGGGAGGAGAAGAGGATCAC
Enzyme Bsa HI
g.3C > T3 Primer CCACAGAGCCACAGAGCTGCC 63.7
Primer GGGCTGGGTGAATTGTGTCATCCT
Enzyme Hinc II
g.1477C > T2 Primer GGAGCCTCTTGCCCATAACA 63
Primer CTACTACCCTGGATTGAGCG
Enzyme Rsa I
g.1591T > C2 Primer CAAATTTGGGTAATGATGTA 56
Primer TTCTACTACCCTGGATTGAG
Enzyme Mae III
g.918A > G2 Primer CCTGTCGGAGTGTAACCTTGGGC 63
Primer TGAGGGAGCTGAGAGGCCAGG
Enzyme Bcc I
1Nucleotide positions are based on GenBank:FJ590753.
2Nucleotide positions are based on GenBank:FJ590751.
3Nucleotide positions are based on GenBank:FJ590752.
Table 4 Haplotypes with frequencies > = 1.0% as determined by PHASE.
Haplotype 1 2 3 4 5 6 7 8
Marker
g.371T > C1 T C T C T T T C
g.986A > G1 A G A G A A A G
g.598T > C2 C T T T C C T T
g.655C > T2 C C C C T C C C
g.918A > G2 A G A A A A G G
g.1131C > G2 C G C C C G G C
g.1456C > G2 C C G G C C C C
g.1477C > T2 T C C C T T C C
g.1591T > C2 C T C C C C T T
g.17361G > A2 A G G G A A G G
g.17918T > G2 G T T T G G T T
g.18059C > T2 C T T T C C T C
g.18308G > A2 G G A A G G G G
g.18390A > T2 A T A A A A T A
g.3C > T3 C T C C C C T C
g.152T > C3 T C C C T T C T
g.1104C > T3 C C T T C C C C
Haplotype Frequency (%) 71.2 10.1 6.0 1.4 1.2 1.0 1.0 1.0
Haplotype Frequency in captive animals (%) 70.6 10.3 6.2 1.1 1.2 1.1 1.1 1.1
Haplotype Frequency in free-ranging animals (%) 78.6 7.4 4.3 4.2 0.0 0.0 0.0 0.0
1Nucleotide positions are based on GenBank:FJ590753.
2Nucleotide positions are based on GenBank:FJ590751.
3Nucleotide positions are based on GenBank:FJ590752.
White et al. BMC Research Notes 2010, 3:314
http://www.biomedcentral.com/1756-0500/3/314
Page 5 of 7
(OR = 0.43, 95%CI: 0.25-0.75). However, after account-
ing for 132L no other variants showed significant asso-
ciation with CWD even on a nominal basis (P > 0.05),
before any correction for multiple testing. The statistical
tests specifically included comparison of CWD fre-
quency among carriers of two haplotypes (2 and 7) that
harbor L132, but no significant differences were
observed (P = 0.99). Furthermore, all genotypes with
any appreciable frequency showed CWD positive
animals, suggesting that there is no complete resistance
to CWD on the basis of common PRNP genotypes in
these elk. While we are not aware of any epidemiologi-
cal evidence to suggest that truly CWD resistant elk
exist, future research could examine the possibility that
complete genetic resistance to CWD does exist in
Rocky Mountain elk, either because of a very low fre-
quency PRNP allele or because of the influence of other
genes.
Figure 1 PRNP gene regions sequenced, haplotype-tagging markers used, and linkage disequilibrium between haplotype-tagging
markers. Sequenced regions totalling >7 kb from a genomic region spanning approximately 63 kb are shown in the upper portion of the
figure as gray bars, with exons shown in larger bars. The open reading frame of PRNP is shown as the blue segment labelled “ORF.” Haplotype-
tagging markers are marked on sequenced regions as black or white bars to show position. Linkage disequilibrium between haplotype-tagging
was measured by D’ and is shown in the lower portion of the figure.
Table 5 Sequenced regions and variants observed
Sequenced Region Total Sequence (bp)/Not
Previously Reported
GenBank
Accession
Total Variants Observed/Not
Previously Reported
dbSNP Accessions
5’ of PRNP 1152/1152 FJ590753 9/9 ss115456948-115456956
PRNP Promoter & Exon 1 2526/79 FJ590751 41/15 ss119994789-119994829
PRNP Exon 2 469/469 FJ590751 3/3 ss120037871-120037873
PRNP Exon 3 (including
CDS & 3’ UTR)
2339/272 FJ590751 10/2 ss119994830-119994833
ss119994835-119994840
3’ of PRNP 1168/1168 FJ590752 12/12 ss115456958-115456969
Total PRNP Gene Region 7654/3140 - 75/41 -
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Additional material
Additional file 1: Amplification primers and conditions. Primer
sequences, strand directions, base positions relative to reference
sequences, annealing temperatures, and included region descriptions.
Additional file 2: Sequencing primers. Primer sequences, strand
directions, base positions relative to reference sequences, and
descriptions of regions sequenced using each primer.
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